Clinical trial NCT06006117: Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Official title: Phase III, Multicenter, Open Label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Marginal Zone Lymphoma
Keywords: Bispecific antibodies, Subcutaneous
Step-up dosing
Marginal Zone Lymphoma
Investigator choices
R/R MZL
Lead sponsor: The Lymphoma Academic Research Organisation
Sponsor class: OTHER
First posted: 2023-08-23
Enrollment: 260
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Arm A - Experimental arm: Mosunetuzumab-Lenalidomide

Arm B - Comparator arms (Investigator Choices):

* Rituximab-Lenalidomide
* Rituximab-Bendamustine
* Rituximab-CHOP
Primary purpose: TREATMENT

Brief summary: This is an open label, multi-center, international, randomized phase III trial to compare the efficacy of Mosunetuzumab-Lenalidomide with investigator choices exclusively in R/R MZL patients. Patients with a proven diagnosis of EMZL, SMZL or NMZL subtypes and previously treated with at least one prior systemic treatment and not more than three prior lines are eligible. Previous treatment line must include at least one systemic line with a drug targeting CD20 (monoclonal antibody at least 2 cycles) with or without chemotherapy (R-CHOP, R-Bendamustine, R-CVP, R-Chlorambucil at least 2 cycles) or targeted treatment such as Ibrutinib.

The patients will be Randomized as follows:

Arm A - Experimental arm:

• Mosunetuzumab-Lenalidomide

Arm B - Comparator arms ( Investigator Choices):

* Rituximab-Lenalidomide
* Rituximab-Bendamustine
* Rituximab-CHOP

Detailed description: This is an open label, multi-center, international, randomized phase III trial to compare the efficacy of Mosunetuzumab-Lenalidomide with investigator choices exclusively in R/R MZL patients. Patients with a proven diagnosis of EMZL, SMZL or NMZL subtypes and previously treated with at least one prior systemic treatment and not more than three prior lines are eligible. Previous treatment line must include at least one systemic line with a drug targeting CD20 (monoclonal antibody at least 2 cycles) with or without chemotherapy (R-CHOP, R-Bendamustine, R-CVP, R-Chlorambucil at least 2 cycles) or targeted treatment such as Ibrutinib.

Patients are stratified according to MZL subtypes and time to progression of disease after first-line within 2 years (POD24) \< 2 years or \> 2 years.

Mosunetuzumab will be administered sub-cutaneously (SC) (21 days first cycle, then 28 days next cycles) and Lenalidomide will be given PO 20 mg/day from Day 1 to Day 21 from cycles C2 to C6. For each patient, investigator choice had to be decided before randomization between Rituximab-Lenalidomide and Rituximab-chemotherapy (R-Bendamustine or R-CHOP).

The primary efficacy endpoint for comparison is the Progression-free survival (PFS) as determined by investigator (Lugano criteria 2014). Secondary objectives include CR24 as determined by investigator (at 24 months) according to Lugano criteria 2014 and by central review based on PET result, Overall response rate (ORR) and CR other than CR24 as determined by investigator, or by central review based on PET result according to Lugano Criteria 2014. 260 patients are planned to be enrolled in France, Belgium, Germany, Italy and Portugal

Eligibility criteria: Inclusion Criteria:

1. Have a diagnosis of MZL, of extranodal (EMZL) or splenic (SMZL based on the Matutes score and CD20 + CD11c + CD180 + CD43 + CD200 expression and validated by a centralized review) or nodals (NMZL) subtypes. In case of large dissemination, disseminated MZL will be included as DMZL and included in NMZL subtype.
2. Have been treated with at least one prior systemic treatment and not more than three prior lines. Previous line must include at least one systemic line with a drug targeting CD20 (monoclonal antibody at least 2 cycles) with or without chemotherapy (R-CHOP, R-Bendamustine, R-CVP, R-Chlorambucil at least 2 cycles) or targeted treatment such as Ibrutinib (at least 1 month). Patients should not have received Lenalidomide before. Prior local therapy (including surgery, radiotherapy antibiotics for H. pylori-positive gastric lymphoma, and antiviral for hepatitis C virus) is not considered as one line of treatment
3. Signed Informed Consent Form
4. Age ≥ 18 years at the time of signing the informed consent form
5. Ability to comply with the study protocol and procedures and required hospitalizations, in the investigator's judgement
6. Eastern Cooperative Oncology Group (ECOG) performance score (PS) of ≤ 2
7. Have a symptomatic disease requiring a systemic treatment
8. Not eligible for a local treatment including radiotherapy or surgery
9. Stage I disease of EMZL, SMZL or NMZL may be eligible only if not candidate to local therapy (surgery or radiotherapy).
10. Measurable disease in at least two perpendicular dimensions on an imaging scan is defined as: lymph node or nodal mass bi-dimensional measurement with ≥ 15 mm in longest transverse diameter or the short diameter must measure ≥ 10 mm regardless of the longest transverse diameter.

    Spleen is considered as a measurable disease if vertical axis is higher than 13 cm.
11. Adequate hematopoietic function at screening as follows unless cytopenia is clearly due to marrow involvement of MZL or hypersplenism or autoimmune thrombocytopenia:

    11.1. Platelet count ≥ 75 G/L; in cases of thrombocytopenia clearly due to marrow involvement of MZL or hypersplenism or auto-immune thrombocytopenia, platelet count should be ≥ 30 G/L Washout platelet transfusion is 7 days between transfusion and D1 of starting treatment 11.2. Absolute Neutrophil Count (ANC ) ≥ 1 G/L unless neutropenia is clearly due to marrow involvement of MZL or hypersplenism. Granulocyte Colony-Stimulating Factor (G-CSF) is not allowed within 7 days before starting treatment 11.3. Total hemoglobin ≥ 8 g/dL unless anemia is clearly due to marrow involvement of MZL or hypersplenism or autoimmune hemolytic anemia. Washout erythrocyte transfusion is 7 days between transfusion and D1 of starting treatment
12. Serum total bilirubin ≤ 1.5 x the upper limit of normal (ULN) (or ≤3 x ULN for patients with Gilbert syndrome),
13. Aspartate Transaminase (AST) or ALanine Transaminase (ALT) ≤ 2.5 x ULN, unless directly attributable to the patient's MZL
14. Measured or estimated creatinine clearance ≥ 40 mL/min by institutional standard method
15. Patients who are hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (HBcAb) positive, must be negative for hepatitis B virus (HBV) polymerase chain reaction (PCR) to be eligible for study participation. Patients who are hepatitis B surface antigen (HBsAg) negative, hepatitis B surface antibody (anti-HBsAb) positive and hepatitis B core antibody (HBcAb) negative are eligible,
16. 16. Contraception: 16.1. For women of childbearing potential (WOCBP) (refer to section 14.6.1 and 14.6.1.1): Serum test pregnancy at screening and Day 1 before first dose. And then monthly until end of treatment. Efficient contraceptive method is required during the treatment period (including periods of treatment interruption), for at least 28 days after the final dose of Lenalidomide (if applicable), 3 months after the final dose of Mosunetuzumab (if applicable), 6 months after the final dose of chemotherapies (if applicable) and 12 months after the final dose of Rituximab (if applicable).

    16.2. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below: With a female partner of childbearing potential or pregnant female partner, men must remain abstinent or use a condom during the treatment period (including periods of treatment interruption), and for at least 28 days after the final dose of Lenalidomide (if applicable), 3 months after the final dose of Mosunetuzumab and Tocilizumab (if applicable), 6 months after the final dose of chemotherapies (if applicable) and 12 months after the final dose of Rituximab) (if applicable).
17. Patient covered by any social security system (France)

Exclusion Criteria:

1. MZL with histologic transformation to high-grade lymphoma
2. Pregnant or breastfeeding or intending to become pregnant during the study or within 28 days after the final dose of Lenalidomide, 3 months after the final dose of Mosunetuzumab and Tocilizumab (if applicable), 6 months after the final dose of chemotherapies and 12 months after the final dose of Rituximab (if applicable). Women of childbearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of study treatment.
3. Participants who have received any of the following treatments prior to study entry:

   * Treatment with Mosunetuzumab or other CD20/CD3-directed bispecific antibodies
   * Allogeneic stem cell transplant
4. Participants who have received any of the following treatments, whether investigational or approved, within the respective time periods prior to initiation of study treatment:

   * Radiotherapy within 2 weeks prior to the first dose of study treatment
   * Autologous stem cell transplant within 100 days prior to first study treatment
   * Use of monoclonal antibodies within 4 weeks prior to first study treatment
   * Systemic immunosuppressive medications (including, but not limited to, Cyclophosphamide, Azathioprine, Methotrexate, Thalidomide, and anti-tumor necrosis factor agents) within 2 weeks prior to first dose of study treatment (C1D1); Systemic corticosteroid treatment \<20 mg/day prednisone or equivalent and inhaled corticosteroids are permitted. Last dose of corticosteroid ≥20 mg/day prednisone or equivalent will not be permitted during the last 15 days before inclusion.

   Administration of acute, low-dose, systemic immunosuppressant medications (e.g., single dose of 4 mg/day of dexamethasone for nausea or B-symptoms) is permitted during 4 days without washout.

   - Any other anti-cancer investigational therapy within 4 weeks prior to initiation of study treatment.
5. Received a live, attenuated vaccine within 4 weeks before first dose of study treatment, or in whom it is anticipated that such a live attenuated vaccine will be required during the study period or within 5 months after the final dose of study treatment, except for acute pandemic situation such COVID19
6. Active or history of Central Nervous System (CNS) lymphoma or leptomeningeal infiltration
7. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibody therapy (or recombinant antibody-related fusion proteins) - grade 3 and 4
8. Known hypersensitivity to biopharmaceuticals produced in CHO cells or any component of the Mosunetuzumab, Rituximab, Tocilizumab, Lenalidomide, or Thalidomide formulation, including Mannitol
9. Patients unable to receive adequate prophylaxis and/or therapy for thromboembolic events (aspirin or low molecular weight heparin)
10. History of prior malignancy, except for conditions as listed below if patients have recovered from the acute side effects incurred as a result of previous therapy:

    * Malignancies treated with curative intent and with no known active disease present for ≥2 years before enrollment
    * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    * Adequately treated cervical carcinoma in situ without evidence of disease
    * Surgically/adequately treated low grade, early stage I, localized prostate in situ carcinoma
11. Participants with infections requiring IV treatment with antibiotics or hospitalization (Grade 3 or 4) within the last 4 weeks prior to inclusion or known active bacterial, viral (including SARS-CoV-2), fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds),
12. Evidence of any significant, concomitant disease that could affect compliance with the protocol or interpretation of results, including, but not limited to:

    * Significant cardiovascular disease \[e.g., Objective Class C or D heart diseases (cf. Classes of Heart Failure \| American Heart Association)\], myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina)
    * Significant pulmonary disease (such as obstructive pulmonary disease or history of bronchospasm)
    * Clinically significant history of liver disease, including viral or other hepatitis, or cirrhosis
    * Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease. Participants with a history of stroke who have not experienced a stroke or transient ischemic attack in the past 1 year and have no residual neurologic deficits as judged by the investigator are allowed. Participants with a history of epilepsy who have had no seizures in the past 2 years with or without anti-epileptic medications can be eligible.
13. History of confirmed progressive multifocal leukoencephalopathy (PML)
14. Known Positive serologic HIV test at screening
15. Acute or chronic hepatitis C virus (HCV) infection Participants who are positive for HCV antibody must be negative for HCV by polymerase chain reaction (PCR) to be eligible for study participation.
16. Known or suspected history of hemophagocytic lymphohistiocytosis
17. Known or suspected chronic active Epstein-Barr virus (EBV) infection within the last 4 weeks prior to inclusion
18. History of erythema multiforme, Grade ≥3 rash, or blistering following prior treatment with immunomodulatory derivatives
19. History of interstitial lung disease (ILD), drug-induced pneumonitis, and autoimmune pneumonitis
20. Active autoimmune disease requiring treatment
21. History of autoimmune disease, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis; except:

    * Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible.
    * Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.
    * Patients with a history of disease-related immune thrombocytopenic purpura or autoimmune hemolytic anemia may be eligible.
    * Patients with a remote history of, or well-controlled autoimmune disease, with a treatment-free interval from immunosuppressive therapy for 12 months may be eligible after review and discussion with the Medical Monitor.
22. Recent major surgery with risk of bleeding within 4 weeks prior to first study treatment administration (C1D1)
23. History of solid organ transplantation
24. Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes an individual's safe participation in and completion of the study
25. Person deprived of his/her liberty by a judicial or administrative decision
26. Person hospitalized without consent
27. Adult person under legal protection
28. Adult person unable to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness
29. Patient unable to receive at least one of the three regimens of the comparator arm (ICT). As in usual practice, physician has to verify the absence of contraindication to the use of the drugs, hypersensitivity, and to take into account the lymphoma history and previous treatment scheme used.

Primary outcomes:
measure: Progression-free survival (PFS) as determined by investigator
timeFrame: After 122 events = approximately 4.5 years and after 163 events = approximately 6.5 years (event = progression or death)
Secondary outcomes:
measure: Complete Response rate (CR) as determined by investigator (CR24)
timeFrame: 2 years
measure: Complete response rate (CR) by blinded central review (CR24)
timeFrame: 2 years
measure: Overall response rate (ORR) as determined by investigator
timeFrame: 6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine
measure: Overall response rate (ORR) as determined by investigator
timeFrame: 12 months
measure: Overall response rate (ORR) as determined by investigator
timeFrame: 24 months
measure: Overall response rate (ORR) as determined by investigator
timeFrame: 36 months
measure: Overall response rate (ORR) as determined by investigator
timeFrame: 48 months
measure: Overall response rate (ORR) as determined by investigator
timeFrame: 60 months
measure: Overall response rate (ORR) by blinded central review
timeFrame: 6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine
measure: Overall response rate (ORR) by blinded central review
timeFrame: 12 months
measure: Overall response rate (ORR) by blinded central review
timeFrame: 24 months
measure: Overall response rate (ORR) by blinded central review
timeFrame: 36 months
measure: Overall response rate (ORR) by blinded central review
timeFrame: 48 months
measure: Overall response rate (ORR) by blinded central review
timeFrame: 60 months
measure: CR rate other than CR24 as determined by investigator
timeFrame: 6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine
measure: CR rate other than CR24 as determined by investigator
timeFrame: 12 months
measure: CR rate other than CR24 as determined by investigator
timeFrame: 24 months
measure: CR rate other than CR24 as determined by investigator
timeFrame: 36 months
measure: CR rate other than CR24 as determined by investigator
timeFrame: 48 months
measure: CR rate other than CR24 as determined by investigator
timeFrame: 60 months
measure: CR rate other than CR24 by blinded central review
timeFrame: 6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine
measure: CR rate other than CR24 by blinded central review
timeFrame: 12 months
measure: CR rate other than CR24 by blinded central review
timeFrame: 24 months
measure: CR rate other than CR24 by blinded central review
timeFrame: 36 months
measure: CR rate other than CR24 by blinded central review
timeFrame: 48 months
measure: CR rate other than CR24 by blinded central review
timeFrame: 60 months
measure: Duration of response (DOR)
timeFrame: 6.5 years
measure: Event-free survival (EFS)
timeFrame: 6.5 years
measure: Time to next anti-lymphoma treatment (TTNLT)
timeFrame: 6.5 years
measure: Histological transformation rate
timeFrame: 6.5 years
measure: Safety: incidence and severity of Adverse Events (AE), of Serious Adverse Events (SAE), of Cytokine Release Syndrome (CRS), of AE grade 3 or 4 of study-drug_related events, incidence of Death and Secondary Primary Malignancies
timeFrame: 6.5 years
measure: Tolerability : number of dose interruptions, dose reductions, and dose intensity, and study treatment discontinuation because of adverse events
timeFrame: 6.5 years
measure: Health related quality of life as measured by the EQ-5D-5L
timeFrame: 7 months
measure: Health related quality of life as measured by the EQ-5D-5L
timeFrame: 12 months
measure: Health related quality of life as measured by the EQ-5D-5L
timeFrame: 24 months
Other outcomes:
Locations:
city: Anderlecht
country: Belgium
facility: INSTITUT JULES BORDET - Service Hématologie
city: Brussels
country: Belgium
facility: UNIVERSITE CATHOLIQUE DE LOUVAIN SAINT-LUC - Service Hématologie
city: Gent
country: Belgium
facility: UNIVERSITAIR ZIEKENHUIS GENT - Service Hématologie
city: Yvoir
country: Belgium
facility: CHU UCL NAMUR - SITE GODINNE - Service Hématologie
city: Amiens
country: France
facility: CHU d'Amiens
city: Avignon
country: France
facility: CH d'Avignon - Hopital Henri Duffaut
city: Bayonne
country: France
facility: CH de la Côte Basque - Hôpital de Bayonne
city: Besançon
country: France
facility: CHRU Besançon - Hôpital Minjoz
city: Bordeaux
country: France
facility: Institut Bergonié
city: Clermont Ferrand
country: France
facility: Chu Estaing
city: Créteil
country: France
facility: CHU Henri Mondor
city: Dijon
country: France
facility: CHU de Dijon
city: La Tronche
country: France
facility: CHU de Grenoble - Hôpital Albert Michallon
city: Lille
country: France
facility: CHRU de LILLE - Claude Huriez
city: Marseille
country: France
facility: Institut Paoli Calmette
city: Montpellier
country: France
facility: CH Saint-Eloi
city: Nancy
country: France
facility: CHU de Nancy - Brabois
city: Nantes
country: France
facility: Centre Catherine de Sienne
city: Nantes
country: France
facility: CHU de Nantes - Hôtel Dieu
city: Nice
country: France
facility: Centre Antoine Lacassagne
city: Nice
country: France
facility: CHU de Nice
city: Orleans
country: France
facility: CHR d'Orléans
city: Paris Cedex 10
country: France
facility: APHP - Hôpital Saint Louis
city: Pierre-Bénite Cedex
country: France
facility: CHU Lyon Sud
city: Rennes
country: France
facility: CHU de Rennes - Hôpital de Pontchaillou
city: Rouen
country: France
facility: Centre Henri Becquerel
city: Saint-Priest-en-Jarez
country: France
facility: Institut de Cancérologie de la Loire Lucien Neuwirth
city: Lisboa
country: Portugal
facility: INSTITUTO PORTUGUES DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL - Departamento Hematologia
Study officials:
affiliation: Lymphoma Study Association
name: Catherine THIEBLEMONT, Pr
role: PRINCIPAL_INVESTIGATOR
affiliation: Lymphoma Study Association
name: Sylvain CARRAS
role: PRINCIPAL_INVESTIGATOR
References: